Modality
Vaccine
MOA
TYK2i
Target
Nectin-4
Pathway
PI3K/AKT
CKDHSMCL
Development Pipeline
Preclinical
Aug 2025
→ Aug 2028
PreclinicalCurrent
NCT04268706
179 pts·MCL
2025-08→2028-08·Not yet recruiting
179 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-08-092.4y awayInterim· MCL
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Preclinical
Not yet…
Catalysts
Interim
2028-08-09 · 2.4y away
MCL
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04268706 | Preclinical | MCL | Not yet recr... | 179 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Olpainavolisib | Moderna | Phase 1 | Menin |